Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epix Pharmaceuticals has resubmitted the new drug application for its novel blood pool magnetic resonance angiography agent, Vasovist to the FDA.
Subscribe to our email newsletter
If approved, Vasovist will be the first contrast agent approved for marketing in the US for use with magnetic resonance angiography (MRA), a non-invasive modality for imaging blood vessels.
Epix’s Vasovist is an injectable intravascular contrast agent designed to provide improved imaging of the vascular system through magnetic resonance angiography imaging.
Michael Kauffman, CEO of Epix, said: “We look forward to continuing to work with the FDA to bring Vasovist to market in the US. We remain hopeful that we will achieve approval for Vasovist by the end of 2008 and are focused on executing our strategy to monetize our interest in this valuable asset.”